文献速递炎症性肠病

调节微生物组治疗克罗恩病

Modulating the Microbiome for Crohn's Disease Treatment.
PubMed 文献 · Gastroenterology · 2023-01-24

综述讨论肠道微生物群与宿主免疫的双向相互作用,以及益生菌和益生元方法诱导的微生物群变化及其潜在临床后果,包括生物膜形成。以克罗恩病为慢性病模型,提出设计能改变疾病状态下宿主微生物群的益生菌的系统方法。

要点

  • 肠道细菌与真菌群落的多种微生物跨界相互作用是潜在治疗开发的重点。
  • 微生物群可影响宿主对药物的免疫反应,可能改变药物结构、生物利用度、活性或毒性。
  • 生物膜形成可改变肠道通透性、增强抗菌药物耐药性并改变宿主免疫反应有效性。

核心结论

  • 理解微生物组的有效变化如何增强治疗疗效,可能解锁通过自然方法调节肠道微生物组以改善治疗的可能性。

研究设计与样本

  • 综述,讨论微生物与宿主之间的潜在双向相互作用,以及益生菌和益生元方法诱导的肠道微生物群变化及其潜在临床后果。

主要发现

  • 微生物群组成可受宿主免疫反应、疾病特异性治疗、抗菌药物和整体生态系统影响。
  • 肠道微生物群可通过潜在转化药物结构并改变生物利用度、活性或毒性来影响宿主对药物或治疗的免疫反应。
  • 生物膜形成的负面后果包括改变肠道通透性、增强抗菌药物耐药性和改变宿主免疫反应有效性。
  • 使用益生菌和益生元方法的自然调节可用于影响宿主微生物组。

临床怎么用

  • 作者以克罗恩病为模型慢性病,提出设计能够改变疾病状态下宿主微生物群的益生菌的系统方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The central role of the gut microbiota in the regulation of health and disease has been convincingly demonstrated. Polymicrobial interkingdom interactions between bacterial (the bacteriome) and fungal (the mycobiome) communities of the gut have become a prominent focus for development of potential therapeutic approaches. In addition to polymicrobial interactions, the complex gut ecosystem also mediates interactions between the host and the microbiota. These interactions are complex and bidirectional; microbiota composition can be influenced by host immune response, disease-specific therapeutics, antimicrobial drugs, and overall ecosystems. However, the gut microbiota also influences host immune response to a drug or therapy by potentially transforming the drug's structure and altering bioavailability, activity, or toxicity. This is especially true in cases where the gut microbiota has produced a biofilm. The negative ramifications of biofilm formation include alteration of gut permeability, enhanced antimicrobial resistance, and alteration of host immune response effectiveness. Natural modulation of the gut microbiota, using probiotic and prebiotic approaches, may also be used to affect the host microbiome, a type of "natural" modulation of the host microbiota composition. In this review, we discuss potential bidirectional interactions between microbes and host, and we describe the changes in gut microbiota induced by probiotic and prebiotic approaches as well as their potential clinical consequences, including biofilm formation. We outline a systematic approach to designing probiotics capable of altering the host microbiota in disease states, using Crohn's disease as a model chronic disease. Understanding how the effective changes in the microbiome may enhance treatment efficacy may unlock the possibility of modulating the gut microbiome to improve treatment using a natural approach.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gowen R, Gamal A, Di Martino L, et al. Modulating the Microbiome for Crohn's Disease Treatment. Gastroenterology. 2023. PMID: 36702360. doi:10.1053/j.gastro.2023.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。